US › Healthcare

SpyGlass Pharma, Inc. (SGP)

US · Healthcare · Biotechnology

$24.11+6.31%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-13.8M
EPS
$-0.69
EPS estimate
$-0.36

EPS came in at -0.69 against a street estimate of -0.36 — a miss of 91.7%.

Key statistics

Market cap
$758.3M
Forward P/E
0.0
P/B
3.01
Book value
$7.48
EPS (TTM)
$-1.34
52-week high
$32.44
52-week low
$17.06
50-day MA
$19.97
200-day MA
$23.09

Analyst view

with an average price target of $45.00.

Shareholding

Insiders
4.28%
Institutions
93.27%

Largest institutional holders

FundStake
RA Capital Management, LLC23.99%
NEA Management Company, LLC22.11%
Sands Capital Ventures, LLC7.48%
Samsara BioCapital, LLC6.31%
T. Rowe Price Associates, Inc.2.11%
Vestal Point Capital LP1.99%
JPMorgan Chase & Co1.73%
Deerfield Management Co1.65%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for SpyGlass Pharma, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.